UK markets close in 5 hours 2 minutes

Grifols, S.A. (GRF.MC)

MCE - MCE Delayed price. Currency in EUR
Add to watchlist
15.18-0.19 (-1.24%)
As of 12:12PM CET. Market open.
Sign in to post a message.
  • A
    Alan
    A Singapore wealth fund becomes a strategic investor by investing $1 billion to acquire a minority stake in a Grifols subsidiary with 300 U.S. plasma centers that will remain under Grifols management
  • G
    Greg
    I bought GRFS today at 11.99. Seems cheap…. I think it will make a comeback. Might take some time but I’m in now.
  • G
    Gary
    from my readings, analysts dont like the stock because they are worried the company is over leveraged and took on too much debt. they are worried about the biotest acquisition as well. grfs needed to suspend the dividend to help shore up the balance sheet. ok - that is the negative side. on positive side, if they can successfully absorb biotest and generate a decent return on their investment, and shore up their balance sheet over the next year- this can turn out to be a decent investment. i think it is cheap turnaround play here. gl
  • M
    Mi
    Seems like still in downtrend. Wait for a true reverse point to enter.
  • G
    Gary
    does grfs still pay a dividend? i haven't heard of a cut ..
  • A
    AO Invest
    What's the deal with this stock? Why is at its lowest point in almost 10 years?
  • G
    Gary
    grfs will have some indigestion for a # of years due to the recent acquisitions ...when they come out the other end things will be rosier ...patience ....
  • A
    AO Invest
    Anyone looking at the uptick post-market tonight? The stock was barely moving and sliding downhill the past few months, did a new dividend just get announced?
  • G
    Gary
    i just bought some shares. the earnings estimates are on the upswing and the company is at 52 week low. the dividend is nice and supportable. i think it is a good time to buy some shares.
  • M
    Mi
    New higher high!
  • C
    Chris
    Management must have a look at ADMA...
  • l
    leonard
    GRFS. is in a good position as the largest plasma collector and already has a contract with BARDA:

    https://www.jwatch.org/

    Early Results Promising for Convalescent Plasma for COVID-19

    By Kelly Young

    Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

    A small, preliminary case series in JAMA shows promise for using convalescent plasma to treat critically ill patients with novel coronavirus disease (COVID-19).

    Researchers in China treated five COVID-19 patients who required mechanical ventilation and had severe pneumonia and high viral load despite taking antivirals. Plasma donors had recovered from SARS-CoV-2 infection and had been symptom-free for at least 10 days. Recipients received 400 mL of convalescent plasma containing neutralizing antibody.

    Within a day of the transfusion, markers of viral load began to improve. All patients saw gradual resolution of pulmonary lesions within 3 days. By day 9, four patients no longer required respiratory support. Three of the patients had been discharged after stays of roughly 50 days. The other two were still hospitalized.

    The authors and editorialists note that the results need to be validated in clinical trials. Last week, the FDA allowed physicians to apply for emergency use of investigational convalescent plasma to treat individual patients.

    LINK(S):

    JAMA article on convalescent plasma (Free)

    JAMA editorial (Free)

    FDA information on investigational convalescent plasma (Free)

    NEJM COVID-19 page (Free)
    NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
    NEJM Journal Watch reviews over 250 scientific and medical journals to present important clinical research findings and insightful commentary
    www.jwatch.org
  • l
    leonard
    Big article in STAT yesterday that the US multi-institutional consortium study on the benefits of convalescent plasma for sick patients with CV19 was strongly suggestive of efficacy; unfortunately, it was not a randomized placebo controlled study. The formal paper is awaiting publication. Under BARDA auspices, convalescent plasma is being converted into immunoglobulin(powder) which enables standardization from batch to batch, and allows for easier storage and administration. The GRFS product has already begun a ph3 study for CV19, both for prophylaxis for exposed individuals and as Rx for sick patients. The chances of success are excellent. The purest play on this theme is GRFS, which is a 15bil market cap biomedical company which specializes in plasma collection and plasma based theraputics. GRFS is one of the few biomedical companies which has failed to get a boost from CV19 and a +ph3 study almost certainly will lead to explosive growth. I am a heavy buyer today. Incidentally, I am a hematologist who did 2 years of immunology research on antibody therapy at NIH
  • N
    Nasdaq Quarterback
    I'm a true long here.. Been in the options for a long time. Based on my data this will move by Sept with a bigger move for November followed by Jan/Feb.
  • A
    Alfonso
    I think this will go up tomorrow due to Trumps FDA plasma news
  • O
    O
    President Donald Trump on Sunday will announce the emergency authorization of convalescent plasma for Covid-19, according to the Washington Post and other reports.
    President Donald Trump on Sunday will announce the emergency authorization of convalescent plasma for Covid-19, according to the Washington Post and other reports.
    www.cnbc.com
  • G
    Gary
    some companies trading at nosebleed levels .this company is cheaply priced. why does it go lower? no sense at all
  • S
    SEVEN
    This stock will never break out.
    up 1 down 1 up .5 down .5

    May be the most boring stock of all time
  • R
    RigDownTex
    WSJ article - Convalescent Plasma Is Safe to Treat Covid-19, National Study Shows
    A study of thousands of Covid-19 patients who received blood plasma transfusions from recovered patients indicates the experimental therapy appears to be safe, paving the way for futurenational-study-finds-convalescent-plasma-to-treat-covid-19-is-safe-11589453869 studies and clinical trials, so says WSJ article.
    https://www.wsj.com/articles/national-study-finds-convalescent-plasma-to-treat-covid-19-is-safe-11589453869
    A study of thousands of Covid-19 patients who received blood plasma transfusions from recovered patients indicates the experimental therapy appears to be safe, paving the way for future studies and clinical trials.
    A study of thousands of Covid-19 patients who received blood plasma transfusions from recovered patients indicates the experimental therapy appears to be safe, paving the way for future studies and clinical trials.
    www.wsj.com
  • G
    Gary
    i like this company but it seems to stagnate. the price should be moving higher. ..